Suite 1300
Salt Lake City, UT 84111
Block-1 3rd Floor, Perungudi Bypass Rd, Perungudi,
Chennai - 600096
MGR Main Rd,
Perungudi, Chennai - 600096
Villupuram,
Tamil Nadu – 605602
Manufacturer Restriction Tracking
Active Tracking of the Manufacturer Restrictions Reshaping the 340B Program
Active tracking of pharmaceutical manufacturer contract pharmacy restrictions — with workflow for dispute filing, resubmission, protected access strategies, and the operational discipline these restrictions evolve quarterly to require. Over 30 manufacturers now restrict contract pharmacy participation
30+
Manufacturers Tracked
QUARTERLY
Restriction Updates
DISPUTE
Workflow Standard
The Reality
Why manufacturer restrictions have become the single biggest threat to hospital 340b savings?
Beginning in July 2020, when Eli Lilly first restricted contract pharmacy participation under 340B, pharmaceutical manufacturers have systematically expanded restrictions on covered entities’ use of 340B in contract pharmacy arrangements. Over 30 major manufacturers now operate restrictions — each with different rules, different dispute mechanisms, different reporting requirements. Hospital 340B programs operating without active restriction tracking face the largest threat to 340B savings since the program’s expansion.
30+ Manufacturers, 30+ Different Restriction Schemes
Eli Lilly, AstraZeneca, Sanofi, Novartis, Merck, Pfizer, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Bayer, Novo Nordisk, AbbVie, J&J, and many more — each restriction has different rules, different excluded drugs, different exception conditions, different reporting demands. Operating across all of them without dedicated infrastructure is impossible to do reliably.
Restrictions Change Quarterly
Manufacturer restriction policies update constantly. New manufacturers add restrictions. Existing manufacturers modify scope. Court rulings change enforcement landscape. Pharmacies operating against last-quarter restriction data face systematic exposure on the policies that have changed.
Contract Pharmacy Models Targeted
Manufacturer restrictions specifically target contract pharmacy arrangements — the most common 340B savings model for hospitals without in-house specialty pharmacies. Hospitals dependent on contract pharmacy for specialty drug 340B economics face direct revenue exposure as restrictions expand.
State Law and HRSA Response Variability
Several states (Arkansas, Louisiana, Mississippi, West Virginia, Kansas, Missouri, and others) have passed laws requiring manufacturers to honor contract pharmacy arrangements. HRSA has referred non-compliant manufacturers for enforcement. The legal landscape is in flux — operational tracking must keep pace with both restrictions AND counter-restrictions.
Dispute and Resubmission Workflow
When a manufacturer restricts a contract pharmacy claim, the covered entity has dispute and resubmission pathways — but they vary by manufacturer, require manufacturer-specific documentation, and operate on different timelines. Without active dispute infrastructure, restricted claims become permanent revenue loss.
Reporting Requirement Compliance
Some manufacturers (Eli Lilly, AstraZeneca, others) require covered entities to submit detailed reporting on contract pharmacy claims to maintain access to certain drugs. Pharmacies that fail to submit required reporting face additional restrictions stacking on top of the original limitations.
Our approach
We run manufacturer restriction tracking as standing operational capability
AnnexMed runs manufacturer restriction tracking as dedicated operational infrastructure — with restriction policy intelligence across 30+ manufacturers, quarterly update workflow, manufacturer-specific dispute and resubmission protocols, state law and HRSA enforcement monitoring, and protected access strategy support. We don’t treat restrictions as a periodic compliance review. We treat them as the active, evolving operational reality they actually are.
We serve hospital 340B programs across DSH hospitals, critical access hospitals, sole community hospitals, FQHCs, Ryan White clinics, and other HRSA-designated entities operating contract pharmacy arrangements where manufacturer restrictions directly threaten 340B savings economics. Our team maintains restriction tracking across the full universe of restricted manufacturers and the dispute mechanisms each maintains.
Recent client results
A 340-bed regional health system operating 23 contract pharmacy arrangements recovered $1.4M in restricted manufacturer claims within the first 6 months of go-live through systematic dispute filing across the major restricted manufacturers. A multi-facility hospital system identified $620,000 in compliance reporting gaps that had triggered additional manufacturer restrictions — closing the reporting gaps restored access to restricted drugs within one quarter. A community hospital with 220 beds adopted manufacturer restriction tracking infrastructure that surfaced state law protections in three operating states, preserving approximately $480,000 in annual contract pharmacy revenue.
30+
Manufacturers Actively Tracked
Quarterly
Restriction Update
Cadence
Standard
Dispute & Resubmission
Workflow
How we support you
End-to-End manufacturer restriction operation
AnnexMed runs manufacturer restriction tracking as a three-stage operation — restriction policy intelligence and quarterly maintenance, manufacturer-specific dispute and resubmission workflow, and state law and HRSA enforcement monitoring — so restrictions get tracked as they evolve, disputes get filed with the right documentation, and protected access strategies get applied where state law or HRSA enforcement creates opportunities.
Restriction Intelligence
30+ manufacturers tracked actively
- Eli Lilly, AstraZeneca, Sanofi, Novartis policies
- Merck, Pfizer, BMS, AbbVie tracking
- Boehringer Ingelheim, GSK, Bayer, Novo Nordisk
- J&J and emerging restricted manufacturer additions
- Quarterly policy update workflow
- Restriction scope and excluded drug maintenance
Dispute & Resubmission
Manufacturer-specific recovery
- Manufacturer-specific dispute pathway protocols
- Required documentation assembly per manufacturer
- Resubmission cycle management
- Aged restricted claim historical sweep
- Reporting requirement compliance
- Dispute outcome tracking
Legal & Enforcement Monitoring
State law and HRSA landscape
- State contract pharmacy protection law tracking
- Arkansas, Louisiana, Mississippi, WV, Kansas, Missouri
- HRSA enforcement referral monitoring
- Court ruling impact assessment
- Protected access strategy application
- Multi-state operating entity coordination
Financial impact
What active restriction tracking means in dollars?
For a hospital 340B program with substantial contract pharmacy reliance, dedicated manufacturer restriction tracking regularly delivers $800K–$3M+ in net annual financial benefit through restricted claim dispute recovery, protected access strategy application, reporting compliance maintenance, and prevented restriction escalation. Most hospitals achieve full ROI on restriction tracking within 5–7 months.
Fast Results
Dispute filing on restricted claims typically begins paying back within the first 90 days as manufacturer-specific protocols activate on accumulated restricted claims. Protected access strategies in state-law-protected operating areas surface within 30 days of go-live.
Built for an Evolving Legal Landscape
Restriction tracking infrastructure adapts as new state laws pass, HRSA enforcement evolves, and court rulings reshape the contract pharmacy landscape. Quarterly maintenance keeps tracking current with both restrictions AND counter-restrictions.
Improvement Area
Estimated Annual Impact
Restricted Manufacturer Claim Dispute Recovery
$400K – $1.4M annually in recovered claims
Historical Restricted Claim Sweep (first 6 months)
$200K – $800K in one-time historical recovery
Protected Access Strategy (state law operating areas)
$150K – $600K annually in state-law-protected revenue
Reporting Compliance Maintenance
$100K – $400K annually in prevented escalation restrictions
Multi-State Operating Entity Coordination
$80K – $300K annually in coordinated restriction strategy
Quarterly Update Capture
$80K – $300K annually in policy-change-current operations
Staffing Cost Reduction / Replacement
$150K – $400K annually
Manufacturer Restriction Tracking Performance Targets
Performance Metric
Industry Benchmark
AnnexMed Target
Manufacturer Coverage
Most vendors cover 6–12 manufacturers
30+ actively tracked
Restriction Update Cadence
Industry standard: Annual or ad-hoc
Quarterly
Dispute Filing Capture Rate
Industry avg: 42–58%
98%+ of disputable claims
Reporting Compliance Rate
Industry varies widely
100% target
State Law Protection Capture
Industry: rarely coordinated
All applicable states
Historical Restricted Claim Sweep
Industry: rarely pursued
Six-month back-look standard
Dispute Resolution Cycle Time
Industry avg: 90–150 days
< 60 days median
Multi-Facility Coordination
Industry: facility-by-facility
Standard
Why AnnexMed?
Periodic restriction review vs. AnnexMed active tracking
Manufacturer restrictions are evolving faster than most pharmacy operations can track. Here’s how AnnexMed compares to typical in-house or generalist 340B operations:
In-House / Traditional
AnnexMed Partnership
Manufacturer Coverage
Top 6–12 manufacturers tracked
30+ manufacturers actively tracked
Update Cadence
Annual or ad-hoc review
Quarterly policy update workflow
Dispute Filing
Inconsistent; aged restricted claims written off
Standard dispute filing across all disputable claims
Reporting Compliance
Best-effort; missed reporting triggers escalations
100% target reporting compliance
State Law Protections
Often missed; legal landscape changes faster than monitoring
Active tracking across all state contract pharmacy protection laws
Historical Recovery
Aged restricted claims absorbed as cost-of-restriction
Six-month historical sweep with systematic recovery
Multi-State Strategy
Facility-by-facility restriction handling
Coordinated multi-state restriction strategy
Cost to Operate
$100K–$140K per FTE for 340B restriction specialist
30–40% lower with no hiring, attrition, or training overhead
Technology
Powered by proprietary AI & analytics
AnnexMed’s technology stack was built for payer-specific operational demands, not adapted from provider-side billing tools. Risk adjustment accuracy, payment integrity, and credentialing compliance each require different data models, workflow logic, and reporting architectures than provider RCM. Our platform reflects that.
AI Agents & Automation
AI Agents & Intelligent Automation deploys autonomous AI agents across the full revenue cycle, automating eligibility verification, prior authorization, claims processing, payment posting, and denial management at hospital scale and speed.
Data & Analytics Platform
Data & Analytics Platform delivers real-time Power BI dashboards built for hospital executive visibility, including system-wide KPIs, service line performance, payer analysis, productivity, financial forecasting, and national benchmarking insights.
Intelligent AR Management
Intelligent AR Management handles A/R follow-up at hospital scale with intelligent worklists prioritized by dollar value and aging, payer-specific follow-up rules, automated escalation for high-value accounts, and full accountability for every claim.
Computer Assisted Coding
Computer Assisted Coding orchestrates hospital coding operation, intelligent chart assignment by service line, TAT tracking with SLA monitoring, quality audits with accuracy scoring, and coder performance management at enterprise scale.
Together, these platforms create a fully instrumented RCM operation where nothing falls through the cracks. You don’t interact with these systems directly, but the results they enable show up directly in your financial performance.
Ready to stop absorbing manufacturer restrictions as cost-of-doing-business?
Trusted by 100+ Healthcare Providers | AAPC, AHIMA & AAHAM Certified | SOC 2 Type II | HIPAA Compliant
Payer client outcomes
$15M–$40M
Risk
Adjustment
$18M–$50M
Payment
Integrity
6 Weeks
Credentialing Clearance
$15M–$50M+
Revenue
Impact
Case Studies
See the impact we deliver
Discover how AnnexMed reduces denials, accelerates reimbursements, and strengthens financial performance. Backed by measurable outcomes and proven RCM expertise, we deliver operational excellence, revenue stability, and sustainable growth you can trust.
Client Voices
See how our clients succeed
Proven RCM expertise. Delivered at scale.
For over 20 years, AnnexMed has delivered RCM solutions nationwide, combining expert billing, coding, and AR support to drive measurable results and growth.
- 20+ years of proven healthcare RCM experience
- 1,500+ professionals supporting billing, coding & AR
- 500+ certified coders across multiple specialties
- 99%+ compliance with HIPAA and security standards
- All 50 states served with consistent, scalable operations
